Co-Diagnostics, Inc. Announces Material Transfer Agreement with ReadyGo

What Happened

• On August 2026, Co-Diagnostics, Inc. (CODX) filed an 8-K (Item 8.01) reporting that it entered into a material transfer agreement with ReadyGo Diagnostics Ltd. under which ReadyGo will provide certain sample collection and preparation materials for feasibility and compatibility testing with Co-Diagnostics’ Co-Dx PCR platform. The Co-Dx PCR platform is being developed for decentralized and point-of-care real-time PCR testing; it is subject to FDA and other regulatory review and is not currently available for sale.

Key Details

• Agreement signed in August 2026 and disclosed in an 8-K filed September 15, 2026.
• ReadyGo will supply sampling materials for evaluation, including technologies aimed at sample collection, cell/biological lysis, nucleic acid stabilization and prep for molecular analysis.
• The agreement is for preliminary evaluation only and does not obligate either party to enter into any development, supply, commercialization or other commercial arrangement.
• No assurances the evaluations will lead to a commercial relationship; Co-Dx platform and tests remain subject to regulatory review.

Why It Matters

• For investors, this is an exploratory step toward potentially simplifying the front end of Co-Diagnostics’ workflow—easier sample collection and prep could make the Co-Dx PCR platform more practical in decentralized/point-of-care settings and expand market opportunity.
• The collaboration is preliminary and non-binding, so it does not guarantee product integration, revenue, or regulatory approval; progress and any commercial terms would require future announcements.